MEDP Stock Recent News
MEDP LATEST HEADLINES
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
MEDP Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / October 14, 2024 / Hagens Berman urges Medpace Holdings, Inc. (NASDAQ:MEDP) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.